PARKIN Inactivation Links Parkinson's Disease to Melanoma.
Fiche publication
Date publication
mars 2016
Journal
Journal of the National Cancer Institute
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand
Tous les auteurs :
Hu HH, Kannengiesser C, Lesage S, André J, Mourah S, Michel L, Descamps V, Basset-Seguin N, Bagot M, Bensussan A, Lebbé C, Deschamps L, Saiag P, Leccia MT, Bressac-de-Paillerets B, Tsalamlal A, Kumar R, Klebe S, Grandchamp B, Andrieu-Abadie N, Thomas L, Brice A, Dumaz N, Soufir N
Lien Pubmed
Résumé
Melanoma incidence is higher in patients affected by Parkinson's disease (PD) and vice versa, but the genetic link shared by both diseases is unknown. As PARK2 is both a tumor suppressor gene and frequently mutated in young onset PD, we evaluated the role of PARK2 in melanoma predisposition and progression.
Mots clés
Adult, Aged, Blotting, Western, Case-Control Studies, Cell Line, Tumor, Cell Proliferation, DNA Copy Number Variations, DNA, Neoplasm, analysis, Female, Frameshift Mutation, France, epidemiology, Gene Dosage, Gene Expression Regulation, Neoplastic, Gene Silencing, Germ-Line Mutation, Humans, Male, Melanocytes, metabolism, Melanoma, epidemiology, Middle Aged, Mutation, Missense, Odds Ratio, Parkinson Disease, epidemiology, Protein Splicing, Risk, Sequence Analysis, DNA, Skin Neoplasms, epidemiology, Tumor Suppressor Proteins, genetics, Ubiquitin-Protein Ligases, genetics
Référence
J Natl Cancer Inst. 2016 03;108(3):